Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02499601
Other study ID # CLD_CRL_0403
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 2015
Est. completion date September 2024

Study information

Verified date June 2020
Source CorAssist Cadiovascular Ltd.
Contact Ruti Hoefler, B.Sc
Email ruti@corassist.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study objective is to demonstrate safety and feasibility of the CORolla® TAA during 12 months of follow up, and to evaluate the performance of the therapy in relieving symptoms and restore diastolic function in patients with heart failure and preserved ejection fraction.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date September 2024
Est. primary completion date September 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria

Clinical criteria:

1. Adult (age > 18 years)

2. Diagnosis of heart failure with preserved ejection fraction

3. NYHA F. Class III or IV or documented history of at least two heart failure hospitalization in the past year prior to enrollment.

4. No contraindication for anticoagulation and antiplatelet treatment.

5. Optimal medical cardiovascular pharmacotherapy with stable doses for at least 4 weeks (not including diuretics)

6. Pulmonary Wedge pressure > 15 mmHg documented by right heart catheterization at enrollment.

7. Patient understands the study requirements and the treatment procedures and provides written Informed Consent before any study-specific tests or procedures are performed

8. Patient is able and willing to adhere to the required follow-up visits and testing

9. Minimal endocardial height from Apex to Mitral Annulus > 60mm at end systole

Echocardiographic criteria:

1. Left ventricular ejection fraction=50%

2. HFpEF diagnosis according to ESC 2016 guidelines

3. No evidence of intra-cardiac thrombus

Cardiovascular disease:

1. Implanted or planned implantation of defibrillator devices such as ICD cardiac resynchronization device (CRT-D) or left ventricular assist device (LVAD).

2. Within the past 3 months - Acute myocardial infarction (AMI), cerebral vascular accident (CVA), or Transient Ischemic Attack (TIA).

3. History of thrombus within the previous 3 months.

4. Coronary Artery Bypass Surgery (CABG), valve replacement or repair, aortic surgery or percutaneous coronary intervention (PCI in the past 3 months or planned/anticipated within the coming 6 months. Patients with mechanical valve replacement or CABG performed more than 3 months before may be eligible for enrollment.

5. Significant valvular disease classified as

- Moderate or severe aortic stenosis/regurgitation

- Moderate or severe mitral stenosis

- Severe mitral regurgitation

6. Hypertrophic cardiomyopathy

7. History of pericardial disease.

8. HF attributed to Cor pulmonale or other cause of isolated right heart failure.

9. Moderate to severe right ventricle failure or right ventricular myocardial infarction.

10. Infiltrative heart disease including amyloidosis.

Non-cardiovascular disease:

1. Prior surgery, radiation, or thoracic surgery limiting the ability to place the device.

2. Moderate to severe asthma or COPD, or severe restrictive lung disease.

3. Severe chronic renal failure indicated by MDRD GFR <30 mL/min/1.73 m2.

4. Liver impairment addressed by bilirubin > 2 mg/dl and serum albumin <3 g/dL

5. Severe anemia addressed by Hb concentration <9 gr/l.

6. Solid organ or hematologic transplant.

7. Previous Trans Apical procedures/implantation.

Miscellaneous conditions:

1. Co-morbid condition that in the physician's opinion would prohibit the subject's ability to meet the protocol requirements.

2. Pregnancy at the time of enrollment. (Women of childbearing potential must have a negative serum pregnancy test within two weeks prior to enrollment, or be using hormonal contraceptives or intrauterine devices).

3. Participating in another treatment investigational study.

4. A history of alcohol abuse, drug addiction, or other psychosocial condition that would preclude successful participation, or clear judgment and informed consent in the opinion of the Principal Investigator.

Study Design


Intervention

Device:
CORolla™ TAA device


Locations

Country Name City State
Israel RAMBAM - Health Care Campus Haifa

Sponsors (1)

Lead Sponsor Collaborator
CorAssist Cadiovascular Ltd.

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with All-cause mortality and Serious Adverse Events (SAEAs) Investigational device safety with the intended study population with respect to 6 months follow up will be demonstrated using the following:
All-cause mortality and Serious Adverse Events (SAEAs) throughout 6 months post-surgery.
6 months
Primary Incidence of in-hospital procedure success. Success of the implant surgical procedure and ability to position the CORolla® TAA will be determined according to Implantation Rating Questionnaire. up ot 24 hour.
Secondary Rate of HF death and re-hospitalization due to HF (including IV diuretic) 6 months
Secondary Rate of HF death and re-hospitalization due to HF (including IV diuretic) 12 months
Secondary Rate, type and severity of procedure related and device-related events 30 days
Secondary Rate of device related Major Adverse Cardiac and Neurological Events (MACNE) up to 6 months
Secondary Change in Quality of Life (QoL) Questionnaire Minnesota Living with Heart Failure. up to 24 months
Secondary Change in New York Heart Association functional Class (NYHA f. Cl). up to 24 months
Secondary Change in exercise capacity as measured by the Six-Minute Walk test. up to 24 months
Secondary Device impact on diastolic dysfunction markers assessed by conventional echocardiography imaging and novel approach including Tissue Doppler Imaging (TDI). Composite measure: Left atrial volume index [ml/m^2], Early mitral flow velocity E [ml/sec], Mitral flow velocity during atrial systole A [ml/sec], E/A ratio, Mitral annular velocity e' [mm/sec], Declaration time [msec], E/e' [ml/mm], Left ventricular mass [gr], Ejection fiction [%], Pulmonary venous flow [m/sec], Transmitral flow propagation velocity [cm/sec]. up to 24 months
Secondary Change of Wedge pressure For safety assessment and impact of CORolla ® TAA therapy on this marker of diastolic dysfunction. up to 24 months
Secondary Change in Pulmonary Capillary Wedge Pressure during handgrip/ergometry Applicable only to patients who are in a clinical condition that enables them to have the test and at sites that have the experience and the capabilities to perform this test. up to 24 months
Secondary Change in exercise testing during echocardiography Composite measure: Maximal exercise tolerance defined as the number of metabolic equivalent (METs) at baseline and maximal: Early mitral flow velocity E [ml/sec], Mitral annular velocity e' [mm/sec] and E/e' [ml/mm]. Applicable only to patients who are in a clinical condition that enables them to have the test and at sites that have the experience to perform this test. up to 24 months
Secondary Change in VO2 Max Applicable only to patients who are in a clinical condition that enables them to have the test and at sites that have the experience and the capabilities to perform this test. up to 24 months
Secondary Changes in cardiac medications, including daily diuretic dose. The dose of furosemide [mg/d] and thiazide [mg/d] before and after the procedure and during follow up will be recorded and compared. up to 24 months
See also
  Status Clinical Trial Phase
Recruiting NCT04558450 - Covid-19 Effects on Arterial Stiffness and Vascular Aging (CARTESIAN) N/A
Completed NCT01775865 - Targeting Inflammation to Treat Cardiovascular Aging Phase 2
Terminated NCT01188369 - Effects of Levosimendan in Patients Eligible for Aortic Valve Replacement With Left Ventricular Hypertrophy Phase 4
Recruiting NCT05552521 - Diastolic Dysfunction in Septic Shock and Cardiomyopathy Genetic Variants
Recruiting NCT05438030 - Diastolic Function Assessment With Cardiac Magnetic Resonance Imaging N/A
Completed NCT04128735 - Diastolic Dysfunction in Morbidly Obese Patients Undergo Bariatric Surgery
Completed NCT00689819 - Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients N/A
Recruiting NCT04149990 - Angiotensin-Neprilysin Inhibition in Diastolic Dysfunction After AMI Phase 2
Completed NCT03768752 - Diastolic Dysfunction and Interstitial Lung Edema in Septic Patients
Completed NCT02932436 - Effects of Empagliflozin on Left Ventricular Diastolic Function Compared to Usual Care in Type 2 Diabetics Phase 4
Recruiting NCT05847244 - The Effect of Addition of Metformin In Obese Non- Diabetic Patients With Heart Failure With Preserved Ejection Fraction Phase 2
Enrolling by invitation NCT04190420 - The Transition From Hypertension to Hypertensive Heart Disease and Heart Failure, the PREFERS Hypertension Study
Completed NCT04114474 - Pre-operative Focused Transthoracic Echocardiography for Prediction of Post-operative Cardiac Complications
Not yet recruiting NCT06131008 - Diastology-Guided Management of Decompensated Heart Failure N/A
Completed NCT03110614 - Diastolic Dysfunction and Pauci-inflammatory Acute Exacerbations of COPD
Not yet recruiting NCT02285309 - Perioperative Measurements of Diastolic Function in Cardiac Surgery N/A
Completed NCT01761318 - Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Phase 4
Completed NCT00804518 - Effect of Exercise on Heart Function in Healthy Elderly People N/A
Completed NCT00907439 - Study of the Effect of Inhaled Anesthetics on Diastolic Heart Function Using a Doppler-derived Efficiency Index N/A
Completed NCT01061450 - Simvastatin and Diastolic Dysfunction Phase 4

External Links